Can a simple protein test predict heart trouble in breast cancer patients?
NCT ID NCT06443645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a protein called SGLT2 is linked to heart damage caused by a common type of breast cancer chemotherapy. Researchers will measure SGLT2 levels in blood and cells from 50 women with localized breast cancer before and after treatment. The goal is to find better ways to identify who is at risk for heart problems, so doctors can prevent them in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The recruited population concerns adult patients followed for localized breast cancer and for whom treatment with anthracycline is indicated in the adjuvant or neoadjuvant situation.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient \> 18 years old * Diagnosed with localized breast cancer * Indication for first-line surgery or anthracycline-based chemotherapy. Exclusion Criteria: * History of chemotherapy or targeted therapy or immunotherapy administered before inclusion * Patient currently being treated with anti-SGLT2, conversion enzyme inhibitor or ARA2 * Patient with known heart disease (ischemic, rhythmic, valvular, etc.) * Patient with a Glomerular filtration rate \< 45 mL/min/1.73m² according to the pre-therapeutic assessment * Patient with impaired liver function * Patient who is pregnant or breastfeeding * Patient with a second cancer undergoing treatment * Patient under guardianship or curatorship, protection of justice or deprived of liberty
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Paul Strauss
RECRUITINGStrasbourg, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can dancing ease the exhaustion of breast cancer treatment?
- AI reads tumor slides to match cancer patients with trials
- Lung imaging could reveal the best anesthetic dose for breast surgery
- Can a Dual-Target drug crack resistant gynecologic and breast cancers?
- AI turns routine chest scans into breast cancer detector
- One shot of radiation: can a single dose replace weeks of breast cancer treatment?